Browsing Tag
JNJ-78278343
1 post
JNJ’s pasritamig plus docetaxel advances to Phase 3 after strong early results in metastatic castration-resistant prostate cancer
Johnson & Johnson's pasritamig hits 75% PSA response in taxane-naive prostate cancer patients. What Phase 3 means for JNJ's oncology strategy. Read more.